BioWorld

June 14, 2004

Cellular Genomics Adds $12.6M To Close Third-Round Financing

Cellular Genomics Inc. padded its Series C financing with an additional $12.6 million, closing the oversubscribed round at $34.9 million. (BioWorld Today) Read More

Momentum Growing For Effort To Legalize Drug Importation

NCI, CMS Begin Initiative To Improve Information On Cancer

Nabi Begins Phase IV Trial To Expand Potential For PhosLo

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for Dec. 17, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 17, 2024.

Second insulin receptor offers new therapeutic avenues

BioWorld Science

Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for...

Drug duo to Repare lack in gyno cancers? Phase I shows promise

BioWorld

Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

Mechanism underlying so-called idiopathic autism inception unveiled

BioWorld Science

Investigators at the Institute for Research in Biomedicine (IRB Barcelona) have unraveled how and why the absence of a neuronal microexon in cytoplasmic...